Many individuals suffering from psychiatric disorders, especially severe mental illnesses, are substantially overweight. This overweight condition is compounded by the metabolic side effects of antipsychotic medications.
The shortened life expectancy of people with serious mental illness may partially result from obesity-associated disorders such as diabetes and heart disease, further exacerbated by smoking.
Metformin can decrease the risk of developing diabetes and contribute to weight loss, though its effectiveness can be variable, providing only a modest weight loss of 3 to 5 percent.
Recent developments in GLP-1 receptor agonists like Semaglutide show promise for addressing obesity but largely exclude severe mental illness cases from previous studies.
Collection
[
|
...
]